Helicobacter pylori proteins (H. pylori proteins)

Helicobacter pylori proteins represent the collective proteome of the Gram-negative bacterium H. pylori, which is uniquely adapted to the acidic environment of the human stomach [1]. Among these, the enzyme urease is critical for survival as it catalyzes the hydrolysis of urea into ammonia and carbon dioxide, effectively neutralizing local gastric acidity [2]. Other significant proteins include virulence factors such as Cytotoxin-associated gene A (CagA) and Vacuolating cytotoxin A (VacA), which disrupt host cell signaling and induce apoptosis, contributing to chronic inflammation [3]. These proteins are the primary targets for eradication therapies, where antibiotics like amoxicillin target penicillin-binding proteins to inhibit cell wall synthesis, and clarithromycin targets the 50S ribosomal subunit to halt protein production [4]. Chronic infection driven by these proteins is the leading cause of peptic ulcers and is strongly associated with the development of gastric adenocarcinoma and MALT lymphoma [1][3]. Clinical management relies on identifying these proteins or their activity through diagnostic biomarkers like the urea breath test or stool antigen assays [5]. The emergence of multi-drug resistant strains targeting these essential bacterial proteins has become a global health concern, necessitating the development of new therapeutic strategies [6].

Other names

Helicobacter pylori proteomeH. pylori antigensH. pylori virulence factorsHelicobacter pylori structural proteins

Antibiotics target various H. pylori proteins to inhibit essential processes: beta-lactams (e.g., amoxicillin) inhibit penicillin-binding proteins involved in cell wall synthesis; macrolides (e.g., clarithromycin) and tetracyclines inhibit ribosomal proteins to block translation; fluoroquinolones (e.g., levofloxacin) inhibit DNA gyrase to prevent DNA replication [4].